Pharvaris (PHVS) Stock Price & Analysis
PHVS$33.22+0.40 +1.22%
$2.32B
Market Cap
-10.38
P/E
19.57
Forward P/E
—
Score
PHVS price $33.22 +0.40 +1.22%
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema…
Insights · Dividends · Forecast · Financials · Learn
$2.32B
Market Cap
-10.38
P/E
19.57
Forward P/E
—
Score